We are thrilled to announce that Release Therapeutics is attending the 21st annual WORLDSymposium™ on Lysosomal Disease Research held in San Diego this week, from 3-7 February.
The Company will be represented by Dr. Julien Grogg, CEO of the Company, while Dr. Françoise Piguet, Head of the Technological Innovation Unit for Gene and Cell Therapy (GENOV) at the Paris Brain Institute, RTx’s strategic collaborator, will present the findings of our pivotal study in non-human primates (NHPs).
In 2024, Release Tx and GENOV achieved a significant milestone with the successful implantation of encapsulated Arylsulfatase A (ARSA)-producing human myoblasts in the brains of two NHPs.
In December, the results of the study were endorsed by our Scientific Advisory Board (consisting of leading experts in metachromatic leukodystrophy (MLD), pediatric neurosurgery and gene and cell therapies) as showing an encouraging safety profile and meaningful therapeutic potential for the treatment of MLD.
We look forward to sharing these groundbreaking findings with the lysosomal disease research community at WORLDSymposium 2025 and engaging with fellow scientists, clinicians, and industry leaders who are dedicated to advancing treatments for rare CNS disorders.
If you’ll be in San Diego, don’t miss Dr. Piguet’s presentation—we’d love to connect and discuss how our implantable encapsulated-cell platform is paving a new path for treating MLD and other genetic CNS diseases without gene therapy.
Stay tuned for more updates from the event,
The Release Tx Team
Comments